A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors

Tufia C Haddad, Rui Qin, Ruth Lupu, Daniel Satele, Matthew Eadens, Matthew Philip Goetz, Charles Erlichman, Julian R Molina

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Cilengitide is a potent and selective inhibitor of the integrins αvβ3 and αvβ5. The primary objective of this phase I clinical trial was to establish the maximum tolerated dose and determine safety/tolerability of cilengitide in combination with paclitaxel in patients with advanced solid tumors. Secondary objectives included the evaluation of the preliminary clinical outcomes. Patients and methods: Patients with advanced solid tumors experiencing disease progression on standard treatment were assigned to two different dose levels of cilengitide (2000 mg intravenously once or twice weekly) in combination with fixed-dose, weekly paclitaxel (90 mg/m2 intravenously). Results: Twelve evaluable patients were treated per protocol. A single dose limiting toxicity (DLT) of grade 4 neutropenia was observed at the starting dose level of once weekly cilengitide. There were no grade ≥3 adverse events that occurred with >10% frequency. One patient achieved a partial response to therapy. Five patients experienced stable disease as best response, 3 of which discontinued study participation due to progressive, peripheral neuropathy. Conclusions: Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m2). Further studies evaluating drugs that target this pathway are warranted.

Original languageEnglish (US)
Pages (from-to)1221-1227
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume79
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Paclitaxel
Tumors
Neoplasms
Clinical Trials, Phase I
Maximum Tolerated Dose
Peripheral Nervous System Diseases
Neutropenia
Integrins
Toxicity
Disease Progression
Cilengitide
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cilengitide
  • Paclitaxel
  • Solid tumors
  • Αvβ3 and αvβ5 integrins

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. / Haddad, Tufia C; Qin, Rui; Lupu, Ruth; Satele, Daniel; Eadens, Matthew; Goetz, Matthew Philip; Erlichman, Charles; Molina, Julian R.

In: Cancer Chemotherapy and Pharmacology, Vol. 79, No. 6, 01.06.2017, p. 1221-1227.

Research output: Contribution to journalArticle

@article{937c310831d24ecdb8e6ba68d3c475af,
title = "A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors",
abstract = "Purpose: Cilengitide is a potent and selective inhibitor of the integrins αvβ3 and αvβ5. The primary objective of this phase I clinical trial was to establish the maximum tolerated dose and determine safety/tolerability of cilengitide in combination with paclitaxel in patients with advanced solid tumors. Secondary objectives included the evaluation of the preliminary clinical outcomes. Patients and methods: Patients with advanced solid tumors experiencing disease progression on standard treatment were assigned to two different dose levels of cilengitide (2000 mg intravenously once or twice weekly) in combination with fixed-dose, weekly paclitaxel (90 mg/m2 intravenously). Results: Twelve evaluable patients were treated per protocol. A single dose limiting toxicity (DLT) of grade 4 neutropenia was observed at the starting dose level of once weekly cilengitide. There were no grade ≥3 adverse events that occurred with >10{\%} frequency. One patient achieved a partial response to therapy. Five patients experienced stable disease as best response, 3 of which discontinued study participation due to progressive, peripheral neuropathy. Conclusions: Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m2). Further studies evaluating drugs that target this pathway are warranted.",
keywords = "Cilengitide, Paclitaxel, Solid tumors, Αvβ3 and αvβ5 integrins",
author = "Haddad, {Tufia C} and Rui Qin and Ruth Lupu and Daniel Satele and Matthew Eadens and Goetz, {Matthew Philip} and Charles Erlichman and Molina, {Julian R}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s00280-017-3322-9",
language = "English (US)",
volume = "79",
pages = "1221--1227",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors

AU - Haddad, Tufia C

AU - Qin, Rui

AU - Lupu, Ruth

AU - Satele, Daniel

AU - Eadens, Matthew

AU - Goetz, Matthew Philip

AU - Erlichman, Charles

AU - Molina, Julian R

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose: Cilengitide is a potent and selective inhibitor of the integrins αvβ3 and αvβ5. The primary objective of this phase I clinical trial was to establish the maximum tolerated dose and determine safety/tolerability of cilengitide in combination with paclitaxel in patients with advanced solid tumors. Secondary objectives included the evaluation of the preliminary clinical outcomes. Patients and methods: Patients with advanced solid tumors experiencing disease progression on standard treatment were assigned to two different dose levels of cilengitide (2000 mg intravenously once or twice weekly) in combination with fixed-dose, weekly paclitaxel (90 mg/m2 intravenously). Results: Twelve evaluable patients were treated per protocol. A single dose limiting toxicity (DLT) of grade 4 neutropenia was observed at the starting dose level of once weekly cilengitide. There were no grade ≥3 adverse events that occurred with >10% frequency. One patient achieved a partial response to therapy. Five patients experienced stable disease as best response, 3 of which discontinued study participation due to progressive, peripheral neuropathy. Conclusions: Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m2). Further studies evaluating drugs that target this pathway are warranted.

AB - Purpose: Cilengitide is a potent and selective inhibitor of the integrins αvβ3 and αvβ5. The primary objective of this phase I clinical trial was to establish the maximum tolerated dose and determine safety/tolerability of cilengitide in combination with paclitaxel in patients with advanced solid tumors. Secondary objectives included the evaluation of the preliminary clinical outcomes. Patients and methods: Patients with advanced solid tumors experiencing disease progression on standard treatment were assigned to two different dose levels of cilengitide (2000 mg intravenously once or twice weekly) in combination with fixed-dose, weekly paclitaxel (90 mg/m2 intravenously). Results: Twelve evaluable patients were treated per protocol. A single dose limiting toxicity (DLT) of grade 4 neutropenia was observed at the starting dose level of once weekly cilengitide. There were no grade ≥3 adverse events that occurred with >10% frequency. One patient achieved a partial response to therapy. Five patients experienced stable disease as best response, 3 of which discontinued study participation due to progressive, peripheral neuropathy. Conclusions: Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m2). Further studies evaluating drugs that target this pathway are warranted.

KW - Cilengitide

KW - Paclitaxel

KW - Solid tumors

KW - Αvβ3 and αvβ5 integrins

UR - http://www.scopus.com/inward/record.url?scp=85018740157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018740157&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3322-9

DO - 10.1007/s00280-017-3322-9

M3 - Article

C2 - 28477227

AN - SCOPUS:85018740157

VL - 79

SP - 1221

EP - 1227

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -